GlassScriptPhysician profile
Lisa C Diglio
NPI 1275527061
$5,257.65
in general payments reported to CMS, 2019-2025
45 companies · $1,708 in 2025
The $1,708 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $553 · 2022: $746 · 2023: $1,193 · 2024: $1,058 · 2025: $1,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,958.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $810.81 | 2021-2025 | |
| Novo Nordisk INC | $506.38 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $408.26 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $383.37 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $349.19 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $270.67 | 2021-2024 | Spravato, Xarelto |
| Lilly USA, LLC | $222.97 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Amgen INC. | $208.27 | 2021-2024 | Repatha, Otezla |
| Shield Therapeutics INC | $176.93 | 2023-2025 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.62 | 2022-2025 | Xifaxan, Trulance |
| Pfizer INC. | $166.35 | 2022-2025 | |
| Madrigal Pharmaceuticals | $137.42 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $129.98 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.42 | 2021-2023 | Spiriva Respimat, Stiolto Respimat |
| Insulet Corporation | $94.76 | 2024-2025 | Omnipod |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Diglio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.